DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pnc5km/vital_signs_the) has announced the addition of the "Vital Signs The Analyst's Perspective - January 2016 Issue " report to their offering.
This Vital Signs issues discusses Panasonic Healthcare's completed acquisition of Bayer's Diabetes Care Unit, Thermo Fisher Scientific's acquisition of Affymetrix, several moves in the single cell-genomics market by Bio-Rad, Illumina, Qiagen, and 10x Genomics, and Abbott's acquisition of Alere.
Bayer tried to find a buyer for the business in 2012 and revived efforts to sell it in November. The industry as a whole has been grappling with increased competition and pressure to cut reimbursements from public-sector medical insurers. The company's annual report said the Diabetes Care unit was hit by reimbursement pressure and price decreases in the United States last year. The business had million euros in sales last year and collaborates with a US medical technology company, Medtronic.
- 10x Genomics
- Bayer AG
- Thermo Fisher Scientific
For more information visit http://www.researchandmarkets.com/research/pnc5km/vital_signs_the